加拿大科學(xué)家利用人體骨髓干細(xì)胞在實(shí)驗(yàn)鼠身上生成新血管,。這項(xiàng)成果有望應(yīng)用于治療外周動(dòng)脈疾病等人類疾病,。美國(guó)《血液》（Blood）雜志日前刊登了相關(guān)論文。
加拿大西安大略大學(xué)羅巴茨研究所教授戴維·赫斯領(lǐng)導(dǎo)的研究小組從人體骨髓中提取干細(xì)胞,，并從中分離出3種不同類型的“促血管生成干細(xì)胞”,，然后對(duì)它們進(jìn)行“凈化處理”，從中篩除受污染或可能會(huì)導(dǎo)致感染的干細(xì)胞,，將處理過(guò)的干細(xì)胞注到實(shí)驗(yàn)鼠循環(huán)系統(tǒng)中,。研究人員事先已將這些實(shí)驗(yàn)鼠腿部的一動(dòng)脈血管結(jié)扎，造成腿部局部受損,。他們發(fā)現(xiàn),，被注到實(shí)驗(yàn)鼠循環(huán)系統(tǒng)中的干細(xì)胞聚集在其腿部的缺血區(qū)域，并促成了受損血管的修復(fù),，改善了實(shí)驗(yàn)鼠的血液循環(huán)。
赫斯認(rèn)為,，這項(xiàng)研究在臨床上是可行的,，美國(guó)一家生物醫(yī)藥公司已向美國(guó)食品和藥物管理局提出申請(qǐng)，希望利用這項(xiàng)成果對(duì)休斯敦一家醫(yī)療中心的21名晚期外周動(dòng)脈疾病患者進(jìn)行臨床試驗(yàn),。赫斯說(shuō),，這項(xiàng)研究成果還可以用于治療身體其他部位的缺血癥狀。
外周動(dòng)脈疾病是糖尿病患者常見(jiàn)的嚴(yán)重并發(fā)癥之一,，其主要癥狀是肢體缺血,，會(huì)導(dǎo)致患者肢體疼痛、傷口難以愈合,，嚴(yán)重情況下會(huì)被截肢,。（生物谷Bioon.com）
生物谷推薦原始出處：
Blood March 26, 2009; DOI 10.1182/blood-2008-04-154567.
Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity
Benjamin J. Capoccia, Debra L. Robson, Krysta D. Levac, Dustin J. Maxwell, Sarah A. Hohm, Marian J. Neelamkavil, Gillian I. Bell, Anargyros Xenocostas, Daniel C. Link, David Piwnica-Worms, Jan A. Nolta, and David A. Hess*
1 Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, United States
2 Program in Regenerative Medicine, Krembil Centre for Stem Cell Biology, Vascular Biology Group, Robarts Research Institute, Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada
3 Department of Developmental Biology, Molecular Imagaing Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, United States
4 Division of Hematology, Department of Medicine, University of Western Ontario and the London Health Sciences Centre, London, Ontario, Canada
5 Stem Cell Program, Department of Internal Medicine, University of California, Davis, Sacramento, CA, United States
The development of cell therapies to treat peripheral vascular disease has proven difficult due to the contribution of multiple cell types that co-ordinate revascularization. Here, we characterized the vascular regenerative potential of transplanted human bone marrow (BM) cells purified by high aldehyde dehydrogenase (ALDHhi) activity, a progenitor cell function conserved between several lineages. BM ALDHhi cells were enriched for myelo-erythroid progenitors that produced multipotent hematopoietic reconstitution after transplantation, and contained non-hematopoietic precursors that established colonies in mesenchymal-stromal and endothelial culture conditions. The regenerative capacity of human ALDHhi cells was assessed by intravenous transplantation into immune-deficient mice with limb ischemia induced by femoral artery ligation/transection. Compared to recipients injected with unpurified nucleated cells containing the equivalent of 2-4-fold more ALDHhi cells, mice transplanted with purified ALDHhi cells showed augmented recovery of perfusion and increased blood vessel density in ischemic limbs. ALDHhi cells transiently recruited to the ischemic region but did not significantly integrate into ischemic tissue, suggesting that transient ALDHhi cell engraftment stimulated endogenous revascularization. Thus, human BM ALDHhi cells represent a progenitor-enriched population of several cell lineages that improves perfusion in ischemic limbs after transplantation. These clinically relevant cells may prove useful in the treatment of critical ischemia in humans.
